Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses (Details Textual)

v2.4.0.8
Acquisitions, Investments, and Licenses (Details Textual)
1 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended
Jun. 30, 2012
USD ($)
Aug. 31, 2011
USD ($)
Jun. 30, 2013
USD ($)
Jun. 30, 2013
RUB
Jun. 30, 2012
USD ($)
Jun. 30, 2013
USD ($)
Jun. 30, 2012
USD ($)
Dec. 31, 2012
USD ($)
Jun. 30, 2013
Pharmsynthez [Member]
USD ($)
Jun. 30, 2013
RXi Pharmaceuticals Corporation [Member]
USD ($)
Aug. 31, 2011
Neovasc [Member]
Jun. 30, 2013
Neovasc [Member]
USD ($)
Mar. 31, 2013
Cytochroma acquisition [Member]
USD ($)
Jun. 30, 2013
Cytochroma acquisition [Member]
USD ($)
Mar. 04, 2013
Cytochroma acquisition [Member]
USD ($)
Feb. 28, 2013
OPKO Brazil
USD ($)
Aug. 31, 2012
Farmadiet Acquisition [Member]
USD ($)
Transaction
Aug. 31, 2012
Farmadiet Acquisition [Member]
EUR (€)
Jun. 30, 2013
Farmadiet Acquisition [Member]
USD ($)
Jun. 30, 2013
Farmadiet Acquisition [Member]
EUR (€)
Aug. 31, 2012
Farmadiet Acquisition [Member]
Product In Development [Member]
USD ($)
Aug. 31, 2012
Farmadiet Acquisition [Member]
Product In Development [Member]
EUR (€)
Jun. 30, 2013
ALS Acquisition [Member]
USD ($)
Apr. 30, 2012
ALS Acquisition [Member]
USD ($)
Dec. 31, 2012
OURLab [Member]
USD ($)
Jun. 30, 2012
Variable Interest Entity, Primary Beneficiary [Member]
SciVac [Member]
member
Jun. 30, 2013
Variable Interest Entity, Primary Beneficiary [Member]
SciVac [Member]
USD ($)
Aug. 31, 2013
Subsequent Event [Member]
Farmadiet Acquisition [Member]
USD ($)
Acquisitions, Investments, and Licenses (Textual) [Abstract]                                                        
Delivery of common stock           0.9951             20,517,030     64,684 70,421 70,421             7,072,748     585,703
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned     $ 480,000,000     $ 480,000,000                 $ 146,900,000 $ 400,000                 $ 32,900,000      
Share Price     $ 7.03     $ 7.03                                            
Business Acquisition, Share Price     $ 7.00     $ 7.00                                            
Percentage of Shareholding by Chairman of Acquiree Company           5.00%                                            
Percentage of Shareholding by Directors of Acquiree Company           5.00%                                            
Market value per share                             $ 7.16 $ 6.73                 $ 4.65      
Number of trading days                         10 days     10 days 10 days 10 days             15 days     10 days
Business acquisition share price on shares issue                         $ 4.87     $ 4.64                 $ 4.33     $ 7.61
Amount payable on cash or shares on achieving milestones for acquiring a product in development                             190,000,000   1,000,000                      
Contingent consideration     68,900,000     68,900,000   20,000,000             47,700,000   1,200,000                      
Cash paid at closing date                               300,000 8,400,000       300,000     2,400,000 9,400,000      
Stock consideration issued in the transaction is being held in a separate escrow account to secure the indemnification obligations of OURLab                                                 1,732,102      
Aggregate purchase price                             194,612,000   16,000,000 13,500,000     1,300,000 1,000,000   4,000,000        
Cash paid at closing date percentage                                 50.00% 50.00%     25.00% 25.00%            
Percentage of deferred payment paid at our option in cash or shares                                 50.00% 50.00%                    
Percentage of paid on first anniversary of closing date                                 25.00% 25.00%                    
Paid in eighteen months after closing date in percentage                                 25.00% 25.00%                    
Business Acquisition Period for payment                                 18 months 18 months                    
Deferred acquisition payments     5,432,000     5,432,000   6,172,000                 7,800,000 6,800,000                    
Deferred acquisition payments discount                                 600,000                      
Deferred Payment to satisfy indemnify claims                                     3,600,000 2,800,000                
Number of ancillary transactions                                 2 2                    
Percentage for ancillary transaction                                 40.00% 40.00%                    
Issue of common stock / Issue of common stock against acquisition     339,045,029 339,045,029   339,045,029   305,560,763                 250,000 250,000                    
Number of shares issued at closing date                                 125,000 125,000                    
Number of shares issued upon achieving certain milestone                                 125,000 125,000                    
Percentage of amount payable on cash or shares on achieving certain milestone                                 75.00% 75.00%                    
Purchase Consideration in cash at closing into a separate escrow account                                               800,000        
Amount paid upon the legal registration                                             800,000          
Net loss                           8,500,000                            
Issue of common stock shares                 12,000,000 50,000,000                                    
Proceeds to be received from sale of proprietary technology     8,100,000 265,000,000                                                
Deferred Revenue                 9,500,000                                      
Research Funding and Option Agreement Period of Payment                 3 years                                      
Revenue related to our license agreements     5,203,000   294,000 21,052,000 432,000     12,500,000                                    
Milestone payments                   50,000,000                                    
Purchase an additional shares                 13,600,000 17,241,380                                    
Asset Purchase Agreement                 9,600,000 2,500,000                                    
Payments to Acquire Equity Method Investments   2,000,000       13,341,000 2,700,000         1,200,000                                
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions                     2,000,000                                  
Warrants Expiration Period   2 years                                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   1,000,000                                                    
Investment Warrants, Exercise Price   $ 1.25                                                    
Asset Purchase Agreement financing for Rxi                   16,400,000                                    
Amount of share purchased 700,000                                                      
Cocrystal on a fully diluted basis                                                   45.00%    
Additional working capital     742,097,000 [1]     742,097,000 [1]   565,201,000 [1]                                     1,200,000  
Number of members of board of directors                                                   5    
Number of members of board of directors appointed by reporting entity                                                   3    
Percent of board of directors appointed by reporting entity                                                   60.00%    
Acquisitions, Investments, and Licenses (Additional Textual) [Abstract]                                                        
Total assets of equity method investees     108,400,000     108,400,000                                            
Total liabilities of equity method investees     33,000,000     33,000,000                                            
Net losses of equity method investees           $ (33,800,000)                                            
[1] As of June 30, 2013 and December 31, 2012, total assets include $6.0 million and $5.6 million, respectively, and total liabilities include $7.8 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities are those as to which there is no recourse against us. Refer to Note 5.